All News

National certification, advanced specialization, and informatics enhance career longevity and patient safety

Phase 3 data show quarterly cemdisiran injections improve gMG symptoms, either and matches or outperforms all study end points compared to combination therapy.

Make sure your communication is respectful, personalized, and strategic for maximum benefit.

Pharmacy Times interviews Lorin Fisher, PhD, BCACP, on her presentation, “Gabapentin for Pain Management: Well Done or Overdone?,” presented at the SPPCP conference. Fisher discusses the evolving role of gabapentin in pain care, highlighting where evidence supports its use, where it may be overprescribed, and key considerations for pharmacists in optimizing safe and appropriate therapy.

Cannabidiol may have broader applicability across genetic developmental and epileptic encephalopathies (DEEs).

FDA approval expands teplizumab-mzwv to patients 1 year and older, helping delay type 1 diabetes onset for children with stage 2 diabetes.

Cultivating balance and well-being is essential to prevent burnout and foster resilience for future practice.

Bocunebart, a novel anti-PACAP antibody, targets a distinct neurological pathway from existing CGRP therapies.

Phase 3 METEOROID shows IL-6 blocker satralizumab cuts MOGAD relapses 68%, with rapid onset and placebo-like safety.

PTCB credentialing elevates pharmacy technicians’ safety and career commitment, boosts patient trust, and enables efficient delegation—helping reduce medication errors in modern pharmacies.

Ferric carboxymaltose is effective and guideline-endorsed, yet underutilized due to high cost and system-level barriers.

A PharmD diploma is available to BSPh graduates based on time in education and training, licensure by examination, and an evolving professional curriculum.

Geopolitical conflict could affect drug manufacturing and global trade routes, with potential downstream impacts on medication costs and availability.

Cemdisiran’s RNA-targeting mechanism is a compelling new option in the generalized myasthenia gravis treatment landscape.

A new study supports the use of PREVENT equations in routine clinical practice, reinforcing their role in cardiovascular risk assessment and pharmacist-led prevention strategies.

The research highlights the influence of hormonal changes on treatment selection and the need for more tailored, life stage–specific care.

Pharmacy students can apply translational and clinical skills gained in their training to successfully transition into pharmaceutical industry roles.

Learn how pharmacists vet financial planners: CFP credentials, true fiduciary duty, fee transparency, and six questions to avoid costly mistakes.

The data, which were presented at the AAN 2026 Annual Meeting, support the agents’ neurological safety, but longer follow-ups and dedicated outcome trials are needed to confirm these findings.

A tailored APPE rotation combines practice exposures and guided reflections, fostering professional identity formation and personal growth in pharmacy students.

Phase 3 SYMPHONY clinical trial data show reboxetine eases narcolepsy type 1 symptoms, improving functional impairment due to excessive daytime sleepiness (EDS) as well as mood symptoms.

A federal directive to expedite FDA review and expand research pathways for psychedelic therapies signals a potential shift in mental health treatment.

Lowering costs won’t improve health outcomes if the pharmacies dispensing those medications lack the authority, staffing, and infrastructure to function as clinical settings.

Oncology teams can address AI-driven cancer cures with empathy, evidence, and safer next steps to protect patients and trust.

Biological sex and societal gender factors independently—and differently—influence TBI mortality, discharge destination, and long-term cognitive recovery.